Hui-Gene collected $14.2m from investors including WuXi AppTec and the Mayo Clinic-backed Huimei Healthcare Management to progress its gene therapy pipeline toward clinical testing and production.

China-based gene therapy developer Hui-Gene Therapeutics raised more than RMB100m ($14.2m) yesterday in a series A round that included pharmaceutical firm WuXi AppTec. Venture capital firm CD Capital led the round, which included Huimei Healthcare Management – a VC partnership between clinical research firm Mayo Clinic and hedge fund manager Hillhouse Capital –  and which…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.